Why This Pharma Boss Isn’t Chasing the Obesity Hype
Belen Garijo, the CEO of Merck KGaA, says focus on growth and innovation is key to the German group’s future.
Merck RSV therapy cuts respiratory infections by 60% in infants
Merck's (MRK) monoclonal antibody clesrovimab shows cuts RSV infections by 60% in infants, with a strong safety profile. Read ...
Germany's Merck open to more M&A for its Life Science division
German science and technology group Merck is open to more acquisitions for its Life Science business after announcing in May ...
DPA International on MSN1d
German science and tech giant Merck confirms full-year guidance
German science and technology giant Merck on Thursday said it is confident of returning to medium-term growth after a ...
Is Merck & Co., Inc. (MRK) the Most Promising Long-Term Stocks According to Hedge Funds?
We recently compiled a list of 10 Most Promising Long-Term Stocks According to Hedge Funds. In this article, we will look at ...
Merck & Co. (MRK): Strong Growth Driven by Keytruda and New Vaccine Approvals
We recently published a list of 10 Best Medical Stocks to Buy Now. In this article, we are going to take a look at where ...
Two of America’s most prominent Black business leaders have a warning for companies abandoning DEI
Ken Frazier and Ken Chenault said companies retreating from DEI will limit equal opportunities for disadvantaged Americans.
Merck's RSV antibody for infants effective in reducing some types of infections in study
Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing some ...
Merck's Posts More Positive Clesrovimab RSV Candidate Study Data
Merck said the Phase 2b/3 pivotal study evaluating a single dose of clesrovimab administered to healthy preterm and full-term infants met all prespecified endpoints, with consistent results through ...
BioPharma Dive4h
Merck antibody reduces RSV-related disease, hospitalizations in trial
Detailed data from a Phase 2b/3 study of Merck’s treatment clesrovimab should support the company’s efforts to win approval by the 2025-2026 season.
Merck Virus Treatment Shows 60.4% Effectiveness, Reduces Certain Infections In Infants
Merck announces positive results from Phase 2b/3 and interim Phase 3 trials of a monoclonal antibody designed to protect infants from RSV.
Merck KGaA Boss Is Scoffing at the Obesity Hype: Leader Q&A
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.